Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Seminars in Cancer Biology|October 13, 2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerMaria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
JCO Oncology Practice|July 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)Adrienne G Waks, Emily L Chen, Noah Graham, et al.
NPJ Breast Cancer|May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsJan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
NPJ Breast Cancer|May 16, 2020
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerZuzana Kos, Elvire Roblin, Rim S Kim, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain TumorsShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Pageof 10